| Virksomhedsstatus | | NORMAL. |
| Sidst opdateret den 09.02.2015 og
angivet som gældende fra 04.05.2006 (6726
dage). |
Ingen historik.
| Branche | | Andre personlige serviceydelser i.a.n (960900). |
| Sidst opdateret den 24.12.2007 og
angivet som gældende fra 01.01.2008 (6119
dage). |
| Historik | Start | Stop |
|---|
| Andre personlige serviceydelser i.a.n (960900) | 01.01.2008 | |
| Anden servicevirksomhed i øvrigt (930500) | 01.09.2006 | 31.12.2007 |
| Uoplyst (980000) | 04.05.2006 | 31.08.2006 |
| Revisionfravalgt | | false. |
| Sidst opdateret den 11.03.2015 og
angivet som gældende fra 04.05.2006 (6726
dage). |
Ingen historik.
Ingen nuværende registrering.
Ingen historik.
| Telefonnummer | | 20181111. |
| Sidst opdateret den 09.04.2015 og
angivet som gældende fra 09.04.2015 (3464
dage). |
Ingen historik.
| Navne | | MC2 Therapeutics A/S. |
| Sidst opdateret den 04.07.2017 og
angivet som gældende fra 20.06.2017 (2661
dage). |
| Historik | Start | Stop |
|---|
| MC2 Therapeutics A/S | 20.06.2017 | |
| MC2 Therapeutics ApS | 01.12.2016 | 19.06.2017 |
| MC2 BIOTEK ApS | 12.10.2006 | 30.11.2016 |
| BIOTECH AF 4. MAJ 2006 ApS | 04.05.2006 | 11.10.2006 |
| Binavne | | MC2 Biotek A/S. |
| Sidst opdateret den 04.07.2017 og
angivet som gældende fra 22.06.2017 (2659
dage). |
| Historik | Start | Stop |
|---|
| MC2 Biotek A/S | 22.06.2017 | |
| MC2 BIOTEK ApS | 14.12.2016 | 21.06.2017 |
| MC2 Therapeutics ApS | 21.11.2016 | 13.12.2016 |
| MC2 BIOACTIVE ApS | 04.05.2006 | 20.11.2016 |
| Tegningsregel | | Selskabet tegnes af en direktør eller af den samlede bestyrelse. |
| Sidst opdateret den 04.07.2017 og
angivet som gældende fra 22.06.2017 (2659
dage). |
| Fortolkning
(2 tegningsmuligheder)
| | 1 direktør |
| bestyrelsen |
| Historik | Start | Stop |
|---|
| Selskabet tegnes af en direktør eller af den samlede bestyrelse | 22.06.2017 | |
| Selskabet tegnes af direktøren | 08.12.2014 | 21.06.2017 |
Type af revisorbistand:Revisionspåtegning
Navn på revisionsvirksomhed:Deloitte Statsautoriseret Revisionspartnerselskab
Revisionsvirksomhedens CVR-nr.:33963556
Beskrivelse af revisor:State Authorised Public Accountant
Virksomhedens regnskabsklasse:Regnskabsklasse C, mellemstor virksomhed
Grundlag for konklusion (revision):We conducted our audit in accordance with International Standards on Auditing (ISAs) and additional
requirements
applicable in Denmark. Our responsibilities under those standards and requirements are further
described in the "Auditor’s responsibilities for the audit of the consolidated financial statements and the parent financial statements" section of this auditor’s
report. We are independent of the Group in accordance
with the International Ethics Standards Board for Accountants’ International Code of Ethics for Professional
Accountants (IESBA Code) and the additional ethical requirements applicable in Denmark, and we have fulfilled
our other ethical responsibilities in accordance with these requirements and the IESBA Code. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis
for our opinion.
Konklusion (revision):We have audited the consolidated financial statements and the parent financial statements of MC2 Therapeutics A/S for the financial year 01. 01. 2023 - 31. 12. 2023, which comprise the income statement, balance sheet, statement of changes in equity and notes, including a
summary of significant accounting policies, for the Group as well as the Parent, and the consolidated cash flow statement. The consolidated financial statements and the parent financial statements
are prepared in accordance with the
Danish Financial Statements Act.
In our opinion, the consolidated financial statements and the parent financial statements give a true and fair view of the Group's and the Parent's financial position at 31. 12. 2023 and of the results of their operations and the consolidated cash flows for the financial year 01. 01. 2023 - 31. 12. 2023 in accordance
with the Danish Financial Statements Act.
Udtalelse om ledelsesberetningen (revision):Management is responsible for the management commentary.
Our opinion on the consolidated financial statements and the parent financial statements døs not cover the management commentary, and we do not express
any form of assurance conclusion thereon.
In connection with our audit of the consolidated financial statements and the parent financial statements, our responsibility is to read the management
commentary and, in doing so, consider whether the management commentary is materially inconsistent with
the consolidated financial statements and the parent financial statements or our knowledge obtained in the audit or otherwise appears to be materially
misstated.
Moreover, it is our responsibility to consider whether the management commentary provides the information
required by relevant law and regulations. Based on the work we have performed, we conclude that the management commentary is in accordance with
the consolidated financial statements and the parent financial statements and has been prepared in accordance with the requirements in the relevant law and regulations. We did not identify any material misstatement of the management commentary.
Ingen nuværende registrering.
Ingen historik.
Ingen nuværende registrering.
Ingen historik.
Ingen nuværende registrering.
Ingen historik.
LoginOpret gratis brugere-conomic integration